Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The company granted stock options to purchase an aggregate of 87,950 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 60,050 shares of Nurix common stock.
One fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of the employee's date of hire and one forty-eighth of the total number of shares underlying the stock options will vest each month thereafter until the stock option is fully vested on the fourth anniversary of the employee's date of hire, subject to the employee's continued service with Nurix on each such vesting date. The stock options have a term of ten years and an exercise price of $9.73 per share, which is equal to the closing price of Nurix's common stock on the grant date as reported by the Nasdaq Global Market.
One fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the RSU vesting start date, which is April 30, 2025, subject to the employee's continued service with Nurix on the vesting date. Thereafter, one sixteenth of the total number of shares subject to the RSUs shall vest quarterly, until the RSU award is fully vested on the fourth anniversary of the vesting start date, subject to the employee's continued service with Nurix on each such vesting date.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix's partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix's dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine's next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
InvestorsJason Kantor, Ph.D.Nurix Therapeutics, Inc.ir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science Advisorslwolffe@wheelhouselsa.com
MediaAljanae ReynoldsWheelhouse Life Science Advisorsareynolds@wheelhouselsa.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Laird Superfood to Report Second Quarter 2025 Financial Results on August 6, 2025
BOULDER, Colo., July 25, 2025--(BUSINESS WIRE)--Laird Superfood, Inc. (NYSE American: LSF) will report financial results for the second quarter ended June 30, 2025 on Wednesday, August 6, 2025 after market close. Management will host a webcast at 5:00 p.m. ET on the same day to discuss the results. Participants may access the live webcast on the Laird Superfood Investor Relations website at under "Events." About Laird Superfood (NYSE American: LSF) Laird Superfood, Inc. creates award-winning, plant-based superfood products that are both delicious and functional. The Company's products are designed to enhance your daily ritual and keep consumers fueled naturally throughout the day. The Company was co-founded in 2015 by the world's most prolific big-wave surfer, Laird Hamilton. Laird Superfood's offerings are environmentally conscientious, responsibly tested and made with real ingredients. Shop all products online at and join the Laird Superfood community on social media for the latest news and daily doses of inspiration. View source version on Contacts Laird Superfood, Inc. Trevor Rousseauinvestors@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Faraday Future Hosts Successful Capitol Hill Club Reception Showcasing Commitment to American Manufacturing and Innovation
WASHINGTON, July 24, 2025--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ("Faraday Future", "FF" or the "Company"), a California-based global shared intelligent electric mobility ecosystem company, held a well-attended and impactful reception at the Capitol Hill Club this week, drawing over a dozen members of Congress and key stakeholders from across the policy and business landscape. The event served as a platform to highlight Faraday Future's ongoing efforts to bring advanced electric vehicle innovation and manufacturing jobs back to American soil. "We at Faraday Future have expressed our desire to play a role in the great American comeback we are seeing under this Administration, particularly as it relates to the automotive industry, which has been the bedrock of American industry for ages," said John Schilling, Global Director of Communications and Public Relations at Faraday Future. The event featured both FF's cutting-edge FF 91 2.0 electric supercar as well as its recently unveiled FX Super One MPV model. Attendees got a firsthand look at both products and experienced the technology, craftsmanship, and vision driving FF's expansion strategy. FF leadership, including FX CEO Max Ma, also met with staff at the White House earlier this week, which included an open dialogue on a number of policy topics such as tariffs, U.S. manufacturing and innovation. FF looks forward to continuing to work closely with the White House in the near future to promote the long-term prosperity of America's high-end manufacturing sector, centered around the automotive industry and its broader ecosystem. "We were extremely honored by the attendance of numerous members of Congress who were interested in both our vehicles, because who wouldn't be, but more importantly, our story about building and employing American," continued Schilling. "We're committed to expanding production here at home and look forward to working with Congress and the Trump Administration to help make that vision a reality." Faraday Future's leadership emphasized that the company is aligning with the current Administration's vision to reindustrialize America and revitalize core manufacturing sectors. With plans to increase domestic production and invest in U.S. jobs, Faraday is proud to be a part of a new chapter in American innovation. ABOUT FARADAY FUTURE Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company's mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future's flagship model, the FF 91, exemplifies its vision for luxury, innovation, and performance. The FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. FF is committed to redefining mobility through AI innovation. Join us in shaping the future of intelligent transportation. For more information, please visit FORWARD LOOKING STATEMENTS This press release includes "forward looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words "plan to," "can," "will," "should," "future," "potential," and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, among others: the Company's ability to secure necessary agreements to license or produce FX vehicles in the U.S., the Middle East, or elsewhere, none of which have been secured; the Company's ability to homologate FX vehicles for sale in the U.S., the Middle East, or elsewhere; the Company's ability to secure the necessary funding to execute on its AI, EREV and Faraday X (FX) strategies, each of which will be substantial; the Company's ability to secure necessary permits at its Hanford, CA production facility; the Company's ability to secure regulatory approvals for the proposed Super One front grill; the potential impact of tariff policy; the Company's ability to continue as a going concern and improve its liquidity and financial position; the Company's ability to pay its outstanding obligations; the Company's ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company's limited operating history and the significant barriers to growth it faces; the Company's history of losses and expectation of continued losses; the success of the Company's payroll expense reduction plan; the Company's ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company's estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company's vehicles; the Company's ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company's vehicles; current and potential litigation involving the Company; the Company's ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company's indebtedness; the Company's ability to cover future warranty claims; the Company's ability to use its "at-the-market" program; insurance coverage; general economic and market conditions impacting demand for the Company's products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company's control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company's operations in China; the success of the Company's remedial measures taken in response to the Special Committee findings; the Company's dependence on its suppliers and contract manufacturer; the Company's ability to develop and protect its technologies; the Company's ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company's stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the Company's Form 10-K filed with the SEC on March 31, 2025, and other documents filed by the Company from time to time with the SEC. View source version on Contacts Investors (English): ir@ Investors (Chinese): cn-ir@ Media:
Business Wire
24 minutes ago
- Business Wire
Laird Superfood to Report Second Quarter 2025 Financial Results on August 6, 2025
BOULDER, Colo.--(BUSINESS WIRE)--Laird Superfood, Inc. (NYSE American: LSF) will report financial results for the second quarter ended June 30, 2025 on Wednesday, August 6, 2025 after market close. Management will host a webcast at 5:00 p.m. ET on the same day to discuss the results. Participants may access the live webcast on the Laird Superfood Investor Relations website at under 'Events.' About Laird Superfood (NYSE American: LSF) Laird Superfood, Inc. creates award-winning, plant-based superfood products that are both delicious and functional. The Company's products are designed to enhance your daily ritual and keep consumers fueled naturally throughout the day. The Company was co-founded in 2015 by the world's most prolific big-wave surfer, Laird Hamilton. Laird Superfood's offerings are environmentally conscientious, responsibly tested and made with real ingredients. Shop all products online at and join the Laird Superfood community on social media for the latest news and daily doses of inspiration.
